Global Cephalosporin Drugs Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|頭孢菌素藥物的全球市場(2021年∼2028年) Global Cephalosporin Drugs Market - 2021-2028|
|出版日期: 2021年08月06日||內容資訊: 英文 180 Pages||
Cephalosporin Drugs Market Overview
The global cephalosporin drugs market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Cephalosporin drugs are part of the beta-lactams group and they work by interfering with the synthesis of the bacterial cell wall. Some of them are given orally, but most are given by parenteral route. They are typically the second-choice antibiotic, and mainly used in pneumonia, septicemia, meningitis, sinusitis, and UTI treatment. Despite their second-line usage, cephalosporins also have a broader spectrum of activity and are more potent than penicillin.
Cephalosporin Drugs Market Dynamics
The cephalosporin drugs market growth is driven by the rising demand for anti-microbials in various indications, the increasing prevalence of infectious diseases, the increase in funding for the development of antibiotics, increased consumption of cephalosporin, easier availability, and a rise in demand for over-the-counter drugs.
Increasing prevalence of infectious diseases is expected to drive the growth in the forecast period
Increasing prevalence of infectious diseases is expected drive the market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2019, a total of 8,920 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.7 cases per 100,000 population. As per the US Department of Health & Human Services report 2020, about 37,832 people in the United States were diagnosed with HIV in 2018, and 38,000 new HIV infections still occur in the United States. Moreover, it has also been reported that there is a rapid spread of various infectious diseases fueling the market growth.
The rising number of clinical trials for R&D is expected to drive the growth in the forecast period
The rising number of clinical trials for R&D of cephalosporin drugs is also expected to boost the growth of the cephalosporin drugs market over the forecast period. For example, in September 2018, the National Institutes of Health (NIH) granted USD 9.4 million for establishing the Center for Biomedical Research Excellence (COBRE) to address the worldwide threat of drug-resistant pathogens.
Moreover, companies are involved in the strategic development of new products. For instance, in April 2018, Basilea Pharmaceutica Ltd announced that its partner Avir Pharma Inc. launched Basilea's hospital antibiotic Zevtera (ceftobiprole) in Canada. Therefore, all these factors may help the cephalosporin drugs market witness fast growth over the forecast period.
Increasing Food and Drug Administration (FDA) recalls is hindering the market growth
For example, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced a recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.
COVID-19 Impact Analysis
The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted major companies' financial status. Various studies have found that the higher cephalosporin consumption rate and use ratio have lower morbidity and mortality caused by COVID-19 than other antibacterials. For example, according to a research study by Hisaya Tanioka et aol., published in BMJ Journal October 2020, the study results found that penicillins should be avoided use under the condition in COVID-19. Empirical treatment with neuraminidase inhibitors and the combination of cephalosporins and macrolides or quinolones are suggested to be an effective treatment for COVID-19. However, cephalosporins inhibit the SARS-CoV-2, and the study results and the compelling cases imply that cephalosporins may work against the SARS-CoV-2 virus. Also, the cephalosporins combined with macrolides and quinolones may be potentially effective against COVID-19 (SARS-CoV-2). Therefore, there are in vitro and in vivo studies going on to evaluate the potential of generations of cephalosporin for COVID-19.
Cephalosporin Drugs Market Segment Analysis
The fifth-generation segment is expected to hold largest share in this market segment
Fifth-generation cephalosporin drugs are found to be developed in the lab to target resistant strains of bacteria specifically. They are ceftobiprole, ceftaroline, and ceftolozane. In these, ceftobiprole is found to be effective against methicillin-resistant staphylococcus aureus (MRSA).
For instance, according to the UNAIDS, during 2019, the number of new HIV/AIDS cases found globally was around 1.7 million, and about 38 million people were living with HIV globally in the same year.
Ceftobiprole has antipseudomonal characteristics that appear to be less susceptible to the development of resistance. Ceftaroline has also been described as the fifth-generation cephalosporin but does not have the antipseudomonal or VRE coverage of ceftobiprole. The fifth-generation cephalosporins are not active against Pseudomonas species. The market is increasing as it has opened gates for an alternative to treat complicated intra-abdominal infections and complicated urinary tract infections. Moreover, ceftolozane is also combined with the B-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections generally exhibit resistance to all B-lactam antibiotics unless this enzyme is inhibited. Thus, the rising use of combination therapies may drive the market during the forecast period.
For instance, in March 2018, Basilea Pharmaceutica Ltd partnered with Grupo Biotoscana S.L. had launched Basilea's hospital antibiotic Zevtera (ceftobiprole) in Argentina. Also, there has been a notable increase in the fifth-generation cephalosporin drugs such as ceftobiprole and ceftaroline that have been attributed to their ability to kill a wide range of bacteria. Thus, it is expected to drive segment growth over the forecast period due to the aforementioned factors.
The generic cephalosporin drugs segment is expected to hold largest share in this market segment
The generic cephalosporin drugs segment is expected to exhibit the largest growth during the forecast period, as these drugs are available at a very lower cost than branded drugs. Moreover, the pharmacological effects of generic drugs are the same as those of their brand-name counterparts.
The injection segment is expected to hold largest share in this market segment
The injection is the most preferred route of drug administration due to quick drug delivery. Intravenous (IV) cephalosporins are used for more severe infections. This is because IV antibiotics reach the tissues faster, making a big difference if a patient has a serious infection, such as meningitis.
The respiratory tract infections segment is expected to hold largest share in this market segment
The increasing prevalence of respiratory tract infections worldwide is expected to boost the segment growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually.
The retail pharmacies segment is expected to hold largest share in this market segment
The retail Pharmacies segment is expected to dominate during the forecast period. Cephalosporin drugs are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost market growth.
Cephalosporin Drugs Market Geographical Analysis
Asia-Pacific region holds the largest market share of global cephalosporin drugs market
Asia-Pacific region is expected to witness the highest growth due to the rising incidence of infectious diseases, rising healthcare expenditure, and a large population base. Moreover, cefuroxime is a second-generation cephalosporin antibiotic that has a broad-spectrum activity and is commonly used to treat the upper and lower respiratory tract infections, Lyme disease, and genitourinary tract infections. It is readily available and affordable, and it exists in both oral and parenteral forms.
The COVID-19 pandemic has shown a slight impact on this market as the cephalosporins have not proven effective against viruses. B-lactam antibiotics, including cephalosporins, have a bacteriostatic effect. The bacteriostatic action means the action of suppressing the growth of bacteria. B-lactam antibiotics act by inhibiting peptidoglycan synthase, which is an enzyme required for synthesizing bacterial cell walls.
In China, tuberculosis is the most leading cause of death due to infectious diseases among adults. For example, according to the World Health Organization, in 2019, 8,33,000 people fell ill with tuberculosis in China. Further, China is still among the 30 high-burden tuberculosis countries globally, and tuberculosis remains a public health concern.
Cephalosporin Drugs Market Competitive Landscape
The global cephalosporin drugs market is moderately competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Astellas Pharma Inc., Baxter International, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Pharmaceuticals, Macleods Pharmaceuticals Ltd, Mankind Pharma, Merck & Co. Inc., Novartis International AG and Teva Pharmaceuticals, Shionogi & Co. Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In February 2020, Shionogi & Co. Ltd announced that FETROJA (cefiderocol) was now available in the United States for patients 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs). FETROJA (cefiderocol) is a cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore.
Cephalosporin Drugs Market Key Companies to Watch
Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It operates business through two divisions: Innovative medicine, Sandoz. Made up of two business units - Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology - our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines. The company strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science.
Product Portfolio: The company portfolio includes Oncology, Cardiovascular, Renal and Metabolic Medicine, Immunology, Dermatology, Ophthalmology, Neuroscience, Respiratory.
Key developments: In February 2021, Novartis' generics division Sandoz signed an agreement with British drugmaker GlaxoSmithKline (GSK) to acquire its cephalosporin antibiotics brands for up to USD 500 million.
The global cephalosporin drugs market report would provide an access to an approx. 77 market data table, 77 figures and 200 pages.
Global Cephalosporin Drugs Market - By Generation
Global Cephalosporin Drugs Market - By Type
Global Cephalosporin Drugs Market - By Indication
Global Cephalosporin Drugs Market - By Formulation
Global Cephalosporin Drugs Market - By Distribution Channel
Global Cephalosporin Drugs Market - By Region
LIST NOT EXHAUSTIVE